title: Drug safety in the treatment of Crohn's disease.
abstract: The management of Crohn's disease usually consists of a succession of short-term acute phase treatments followed by long-term maintenance therapy. The disease affects young patients and for this reason the long-term safety of the drugs needs to be especially taken into consideration. The safety, dose, duration for optimal efficacy and the most frequent adverse events will be described in this article.
authors.affiliation: Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland.
authors.forename: Pascal
authors.initials: P
authors.lastname: Juillerat
authors.forename: Christian
authors.initials: C
authors.lastname: Felley
authors.forename: Christian
authors.initials: C
authors.lastname: Mottet
authors.forename: Florian
authors.initials: F
authors.lastname: Froehlich
authors.forename: John-Paul
authors.initials: JP
authors.lastname: Vader
authors.forename: Bernard
authors.initials: B
authors.lastname: Burnand
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Gonvers
authors.forename: Pierre
authors.initials: P
authors.lastname: Michetti
mesh_terms: D000305:Adrenal Cortex Hormones / Q000592:standards / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000592:standards / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007166:Immunosuppressive Agents / Q000592:standards / Q000627:therapeutic use*; D012307:Risk Factors; D012449:Safety
chemical_list: D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D007166:Immunosuppressive Agents